Immunic(IMUX) - 2025 Q4 - Annual Results

– Top-Line Data from Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis Expected by Year-End 2026 – Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update – Raised Proceeds of $200 Million in a Private Placement, with Potential for up to an Additional $200 Million – – Net Proceeds Expected to Fund Completion of Phase 3 ENSURE Trials in Relapsing Multiple Sclerosis, Initiation of Phase 3 Trial in Primary Progressive Multiple Sclerosis and Begin of Trans ...